Another win for Novo’s semaglutide? Physicians prefer it most in the emerging field of NASH treatments, survey finds
As fatty liver disease gets a new name, will it also finally get approved drug treatments? That’s what healthcare professionals are hoping for as nonalcoholic fatty liver disease (NAFLD) becomes metabolic dysfunction-associated fatty liver disease (MAFLD), and nonalcoholic steatohepatitis (NASH) becomes metabolic dysfunction-associated steatohepatitis (MASH). The name changes, aimed at getting rid of stigmatizing language […]
A Call for Help from Physician Specialists on the Frontline Treating MASLD/MASH
Spherix Global Insights finds gastroenterologist and hepatologist capacity is being stretched to the limit by increasing demand from MASLD/MASH patients Exton, PA., July 17, 2023 – Data from the Centers for Disease Control & Prevention (CDC) suggests just over seventy percent of American adults are overweight, including 40% being clinically obese. Nearly twenty percent of […]
Riding the Early Adoption Wave Created by Ferring’s Rebyota, Aimmune’s Vowst, is Set to Provide a New Fecal Microbiota Transplant (FMT) Option for Patients Struggling with Recurrent Clostridioides Difficile, According to Spherix Global Insights
Ferring Pharmaceutical’s achieved an innovative milestone in C.Diff treatment when it launched Rebyota, the first FDA approved Fecal Microbiota Transplant (FMT) therapy, earlier this year EXTON, Pa., May 22, 2023 — Prior to Ferring Pharmaceuticals’ Rebyota, physicians interested in using fecal microbiota transplants (FMT) to treat patients with recurrent clostridioides difficile (C.Diff) had to turn […]
The Rising NAFLD/NASH Epidemic Coupled with High Patient Need Offers Opportunities for Pharmaceutical Manufacturers to Capitalize Across Various Disease Stages, According to Spherix Global Insights
New Spherix research highlights existing need for innovation in this underserved population EXTON, Pa., May 22, 2023 — The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in the U.S. Despite the significant size and unmet need of the potential market, pharmaceutical companies have yet to capitalize on the […]
Approximately One Year Post-Launch, AbbVie’s Rinvoq Boasts Increasingly Favorable Perceptions Among Gastroenterologists for the Treatment of Ulcerative Colitis, According to Spherix Global Insights
Recent research suggests AbbVie has managed gastroenterologists’ concerns regarding JAK safety, setting up a potentially favorable encore in the Crohn’s disease market. EXTON, Pa., May 17, 2023 /PRNewswire/ — In March of 2022, the FDA approved AbbVie’s JAK1 inhibitor, Rinvoq (upadacitinib), for the treatment of moderate to severe ulcerative colitis (UC). Of note, however, JAK […]
Over Three Years After Receiving a Complete Response Letter From the FDA, Takeda’s Subcutaneous Formulation of Entyvio (Entyvio SC) is Poised to Enter a Rapidly Evolving UC Market, According to Spherix Global Insights
An FDA approval for Entyvio SC could exacerbate an already aggressive fight for second-line UC treatments. Exton, PA., May 4, 2023 – In December 2019, Takeda Pharmaceutical Company (“Takeda”) announced the receipt of a complete response letter (CRL) for the subcutaneous (SC) formulation of its successful ulcerative colitis (UC) treatment, Entyvio (vedolizumab). The intravenous (IV) […]
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As Well As Novo Nordisk’s Semaglutide Differentiation amongst these pipeline agents will hinge on ease of access, easy-to-use companion diagnostics, and safety EXTON, Pa., July 2022 – Despite multiple high-profile trial failures in early Alzheimer’s disease […]
Diabetes-Related Mechanisms of Action Make Their Move as Several NAFLD/NASH Pipeline Therapies Inch Closer to the First-Ever FDA Approval
Ten NAFLD/NASH pipeline product profiles were evaluated by US gastroenterologists and hepatologists to assess strengths, weaknesses, and physician receptivity EXTON, Pa., June 1, 2022 /PRNewswire/ — Spherix recently surveyed 103 US gastroenterologists and 20 hepatologists, along with conducting eight qualitative interviews (including 2 KOLs and 6 clinical trial participants), to assess the current and future management of […]
Betting on ‘Golden Age’ of Colonoscopies, Investors Buy Up Gastroenterology Practices
In 2021, the number of private equity acquisitions of gastroenterology practices grew by 28% over the previous year, according to Spherix Global Insights and Fraser Healthcare. Complex government regulations, technological innovations, and insurance industry practices have driven many gastroenterologists to sell shares in their practices, said Praveen Suthrum, who runs a consulting company for physician […]
Eylea Keeps its Lead In the Retinal Space as Physicians Remain Hesitant on Roche’s Susvimo — Report
Roche trumpeted a “major advancement” in the retinal space with the approval of its eye drug Susvimo last October, touting it as a more manageable option for patients with wet age-related macular degeneration. However, safety concerns leave some physicians hesitant. While most ophthalmologists have heard of Susvimo — 86%, according to the latest Spherix survey […]
